Claims for Patent: 11,944,611

Summary for Patent: 11,944,611

Title:	Capsid inhibitors for the treatment of HIV
Abstract:	The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
Inventor(s):	Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant, Dana J. Levine
Assignee:	Gilead Sciences Inc
Application Number:	US16/512,166
Patent Claims:	1. A method of treating human immunodeficiency virus (HIV) infection in a heavily treatment-experienced patient, the method comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a sodium salt of the compound of Formula (Ia): one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is in the form of a solution comprising about 10 w/w % to about 40 w/w % water, about 35 w/w % to about 75 w/w % polyethylene glycol 300 (PEG 300), and about 5 w/w % to about 35 w/w % of the sodium salt of the compound of Formula (Ia); wherein the HIV infection is an HIV-1 infection characterized by HIV-1 mutant resistance to one or more antiretroviral medications. 2. The method of claim 1, wherein the HIV-1 mutant is resistant to a protease inhibitor (PI), a nucleoside or nucleotide reverse transcriptase inhibitor (NRTI), a non-nucleoside or non-nucleotide reverse transcriptase inhibitor (NNRTI), or an integrase strand transfer inhibitor (INSTI). 3. The method of claim 1, wherein the patient is infected with HIV-1 resistant to at least one antiretroviral medication. 4. The method of claim 1, wherein the patient is infected with multidrug resistant HIV-1 which is resistant to at least one antiretroviral medication from each of two different classes of antiretroviral medications, wherein the different classes of antiretroviral medications are selected from a nucleoside or nucleotide reverse transcriptase inhibitor (NRTI), a non-nucleoside or non-nucleotide reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), and an integrase strand transfer inhibitor (INSTI). 5. The method of claim 1, wherein the pharmaceutical composition comprising the sodium salt of the compound of Formula (Ia) further comprises one or more other compounds selected from HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV nucleoside reverse transcriptase translocation inhibitors, and pharmacokinetic enhancers. 6. The method of claim 1, wherein the patient has a viral load of greater than about 200 copies of HIV-1 RNA/mL at the time of beginning administration of the compound of Formula (Ia), or a pharmaceutically acceptable salt thereof. 7. The method of claim 6, wherein administration of the pharmaceutical composition comprising the sodium salt of the compound of Formula (Ia) results in a decrease in the viral load in the patient. 8. The method of claim 1, wherein the amount of water in the solution comprising the sodium salt of the compound of Formula (Ia), PEG 300, and water is about 21 w/w % to about 29 w/w %. 9. The method of claim 1, wherein the amount of PEG 300 in the solution comprising the sodium salt of the compound of Formula (Ia), PEG 300, and water is about 50 w/w % to about 59 w/w %. 10. The method of claim 1, wherein the amount of the sodium salt of the compound of Formula (Ia) in the solution comprising the sodium salt of the compound of Formula (Ia), PEG 300, and water is about 13 w/w % to about 27 w/w %. 11. The method of claim 1, wherein the solution comprises about 21 w/w % to about 29 w/w % water, about 50 w/w % to about 59 w/w % PEG 300, and about 13 w/w % to about 27 w/w % of the sodium salt of the compound of Formula (Ia). 12. The method of claim 1, wherein the solution comprises about 23.41 w/w % to about 27.47 w/w % water, about 50.13 w/w % to about 58.84 w/w % PEG 300, and about 13.69 w/w % to about 26.46 w/w % of the sodium salt of the compound of Formula (Ia). 13. The method of claim 1, wherein the solution comprises about 27.47 w/w % water, about 58.84 w/w % PEG 300, and about 13.69 w/w % of the sodium salt of the compound of Formula (Ia). 14. The method of claim 1, wherein the solution comprises about 23.41 w/w % water, about 50.13 w/w % PEG 300; and about 26.46 w/w % of the sodium salt of the compound of Formula (Ia). 15. A method of treating human immunodeficiency virus (HIV) infection in a heavily treatment-experienced patient, the method comprising administering to the patient a therapeutically effective amount of pharmaceutical composition comprising a sodium salt of the compound of Formula (Ia): and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is in the form of a tablet comprising about 5 w/w % to about 45 w/w % of the sodium salt of the compound of Formula (Ia), about 1 w/w % to about 10 w/w % of copovidone, about 0.01 w/w % to about 10 w/w % of poloxamer 407, about 5 w/w % to about 45 w/w % of microcrystalline cellulose, about 15 w/w % to about 70 w/w % of mannitol, about 1 w/w % to about 30 w/w % of croscarmellose sodium, and about 0.01 w/w % to about 10 w/w % of magnesium stearate; wherein the HIV infection is an HIV-1 infection characterized by HIV-1 mutant resistance to one or more antiretroviral medications. 16. The method of claim 15, wherein the tablet is prepared from a spray-dried dispersion technology. 17. The method of claim 15, wherein the amount of the sodium salt of the compound of Formula (Ia) is about 5 mg to about 500 mg. 18. The method of claim 15, wherein the amount of the sodium salt of the compound of Formula (Ia) is about 300 mg. 19. The method of claim 15, wherein the amount of the sodium salt of the compound of Formula (Ia) in the tablet comprising the sodium salt of the compound of Formula (Ia), copovidone, poloxamer 407, microcrystalline cellulose, mannitol, croscarmellose sodium, and magnesium stearate is about 15 w/w % to about 25 w/w %. 20. The method of claim 15, wherein the amount of copovidone in the tablet comprising the sodium salt of the compound of Formula (Ia), copovidone, poloxamer 407, microcrystalline cellulose, mannitol, croscarmellose sodium, and magnesium stearate is about 3 w/w % to about 6 w/w %. 21. The method of claim 15, wherein the amount of poloxamer 407 in the tablet comprising the sodium salt of the compound of Formula (Ia), copovidone, poloxamer 407, microcrystalline cellulose, mannitol, croscarmellose sodium, and magnesium stearate is about 0.5 w/w % to about 3.0 w/w %. 22. The method of claim 15, wherein the amount of microcrystalline cellulose in the tablet comprising the sodium salt of the compound of Formula (Ia), copovidone, poloxamer 407, microcrystalline cellulose, mannitol, croscarmellose sodium, and magnesium stearate is about 18 w/w % to about 30 w/w %. 23. The method of claim 15, wherein the amount of mannitol in the tablet comprising the sodium salt of the compound of Formula (Ia), copovidone, poloxamer 407, microcrystalline cellulose, mannitol, croscarmellose sodium, and magnesium stearate is about 40 w/w % to about 50 w/w %. 24. The method of claim 15, wherein the amount of croscarmellose sodium in the tablet comprising the sodium salt of the compound of Formula (Ia), copovidone, poloxamer 407, microcrystalline cellulose, mannitol, croscarmellose sodium, and magnesium stearate is about 6 w/w % to about 10 w/w %. 25. The method of claim 15, wherein the amount of magnesium stearate in the tablet comprising the sodium salt of the compound of Formula (Ia), copovidone, poloxamer 407, microcrystalline cellulose, mannitol, croscarmellose sodium, and magnesium stearate is about 1.0 w/w % to about 3.0 w/w %. 26. The method of claim 15, wherein the tablet further comprises an outer film coat. 27. The method of claim 15, wherein the outer film coat provides from about 1% to about 8% weight gain based on the uncoated tablet. 28. The method of claim 15, wherein the outer film coat provides about 4% weight gain based on the uncoated tablet. 29. The method of claim 28, wherein the HIV-1 mutant is resistant to a protease inhibitor (PI), a nucleoside or nucleotide reverse transcriptase inhibitor (NRTI), a non-nucleoside or non-nucleotide reverse transcriptase inhibitor (NNRTI), or an integrase strand transfer inhibitor (INSTI). 30. The method of claim 15, wherein the patient is infected with HIV-1 resistant to at least one antiretroviral medication. 31. The method of claim 15, wherein the patient is infected with multidrug resistant HIV-1 which is resistant to at least one antiretroviral medication from each of two different classes of antiretroviral medications, wherein the different classes of antiretroviral medications are selected from a nucleoside or nucleotide reverse transcriptase inhibitor (NRTI), a non-nucleoside or non-nucleotide reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), and an integrase strand transfer inhibitor (INSTI). 32. The method of claim 15, wherein the composition further comprises one or more other compounds selected from HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV nucleoside reverse transcriptase translocation inhibitors, and pharmacokinetic enhancers. 33. The method of claim 15, wherein the patient has a viral load of greater than about 200 copies of HIV-1 RNA/mL at the time of beginning administration of the pharmaceutical composition comprising the compound of Formula (Ia), or a pharmaceutically acceptable salt thereof. 34. The method of claim 33, wherein administration of the pharmaceutical composition the sodium salt of the compound of Formula (Ia) results in a decrease in the viral load in the patient.